Page last updated: 2024-08-17

cytidine monophosphate and nuc-1031

cytidine monophosphate has been researched along with nuc-1031 in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (25.00)	24.3611
2020's	6 (75.00)	2.80

Authors

Authors	Studies
Balzarini, J; Blagden, S; Ghazaly, E; Jiang, WG; Lopez, MH; Mason, M; McGuigan, C; Slusarczyk, M; Thompson, E	1
Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH	1
Abdelrahman, A; Arora, M; Barrett, MT; Bogenberger, JM; Borad, MJ; Braggio, E; Chen, X; Egan, JB; Kasimsetty, A; Kosiorek, HE; Leiting, JL; Lenkiewicz, E; Malasi, S; Nagalo, BM; Salomao, MA; Truty, MJ; Uson, PLS; Zhou, Y	1
Boyd, LNC; Giovannetti, E; Kazemier, G; Peters, GJ	1
Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW	1
Brandi, G; Ricci, AD; Rizzo, A	1
Blagden, SP; Gabra, H; Ghazaly, E; Gnanaranjan, C; Harrison, DJ; Kazmi, F; McCracken, NW; Nicum, S; Roux, RL; Spiers, L; Sukumaran, A	1
Ghazaly, E; Kariuki, BM; McGuigan, C; Pepper, C; Serpi, M; Slusarczyk, M	1

Reviews

1 review(s) available for cytidine monophosphate and nuc-1031

Article	Year
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical oncology (Northwood, London, England), 2020, Jun-11, Volume: 37, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2020

Article

Year

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.

Medical oncology (Northwood, London, England), 2020, Jun-11, Volume: 37, Issue:7

Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome

2020

Trials

1 trial(s) available for cytidine monophosphate and nuc-1031

Article	Year
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-01, Volume: 27, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytidine Monophosphate; Disease-Free Survival; Drug Dosage Calculations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome	2021

Article

Year

A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 06-01, Volume: 27, Issue:11

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytidine Monophosphate; Disease-Free Survival; Drug Dosage Calculations; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome

2021

Other Studies

6 other study(ies) available for cytidine monophosphate and nuc-1031

Article	Year
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. Journal of medicinal chemistry, 2014, Feb-27, Volume: 57, Issue:4 Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans	2014
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031. Scientific reports, 2019, 05-21, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms	2019
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biliary Tract Neoplasms; Cell Proliferation; Cisplatin; Cytidine Monophosphate; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
NUC-1031 in biliary tract cancer: from bench to bedside and back? Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:6 Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cytidine Monophosphate; Humans; Prognosis; Translational Research, Biomedical	2020
In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)". The oncologist, 2021, Volume: 26, Issue:5 Topics: Bile Duct Neoplasms; Cisplatin; Cytidine Monophosphate; Humans	2021
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells Journal of medicinal chemistry, 2021, 06-24, Volume: 64, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cytidine Monophosphate; Drug Screening Assays, Antitumor; Drug Stability; Hepatocytes; Humans; Neoplastic Stem Cells; Stereoisomerism; Uridine Monophosphate	2021